{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:31:27Z","timestamp":1787729487570,"version":"build-2784847793"},"reference-count":31,"publisher":"Japanese Circulation Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,11,25]]},"DOI":"10.1253\/circj.cj-19-0546","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T22:03:21Z","timestamp":1572991401000},"page":"2434-2442","source":"Crossref","is-referenced-by-count":8,"title":["Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries"],"prefix":"10.1253","volume":"83","author":[{"given":"Kazuo","family":"Miyazawa","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Mazurek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Centre for Heart Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Shantsila","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital"},{"name":"Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wolff","sequence":"additional","affiliation":[{"name":"Whinfield Medical Practice"},{"name":"Division of Family Practice, Chilliwack General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Hospital Organization Kyoto Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University of Birmingham"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital"},{"name":"Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the Netherlands. <i>J Am Coll Cardiol<\/i> 2015; 66: 1000\u20131007.","DOI":"10.1016\/j.jacc.2015.06.1314"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation: The Framingham Study. <i>Stroke<\/i> 1996; 27: 1760\u20131764.","DOI":"10.1161\/01.STR.27.10.1760"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Eur Heart J<\/i> 2016; 37: 2893\u20132962.","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. <i>Thromb Haemost<\/i> 2017; 117: 1230\u20131239.","DOI":"10.1160\/TH16-11-0876"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. <i>Lancet<\/i> 2016; 388: 806\u2013817.","DOI":"10.1016\/S0140-6736(16)31257-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: The GLORIA-AF Registry, Phase II. <i>Am J Med<\/i> 2015; 128: 1306\u20131313.e1301.","DOI":"10.1016\/j.amjmed.2015.07.013"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chao TF, Liu CJ, Tuan TC, Wang KL, Lin YJ, Chang SL, et al. Impact on outcomes of changing treatment guideline recommendations for stroke prevention in atrial fibrillation: A nationwide cohort study. <i>Mayo Clin Proc<\/i> 2016; 91: 567\u2013574.","DOI":"10.1016\/j.mayocp.2016.03.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. <i>Circ J<\/i> 2014; 78: 1997\u20132021.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Can J Cardiol<\/i> 2016; 32: 1170\u20131185.","DOI":"10.1016\/j.cjca.2016.07.591"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. <i>Nat Rev Cardiol<\/i> 2014; 11: 639\u2013654.","DOI":"10.1038\/nrcardio.2014.118"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mazurek M, Shantsila E, Lane DA, Wolff A, Proietti M, Lip GYH. Guideline-adherent antithrombotic treatment improves outcomes in patients with atrial fibrillation: Insights from the Community-Based Darlington Atrial Fibrillation Registry. <i>Mayo Clin Proc<\/i> 2017; 92: 1203\u20131213.","DOI":"10.1016\/j.mayocp.2017.05.023"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation: The Euro Heart Survey on Atrial Fibrillation. <i>Am Heart J<\/i> 2007; 153: 1006\u20131012.","DOI":"10.1016\/j.ahj.2007.03.008"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, et al. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry. <i>J Cardiol<\/i> 2013; 61: 260\u2013266.","DOI":"10.1016\/j.jjcc.2012.12.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shantsila E, Wolff A, Lip GY, Lane DA. Optimising stroke prevention in patients with atrial fibrillation: Application of the GRASP-AF audit tool in a UK general practice cohort. <i>Br J Gen Pract<\/i> 2015; 65: e16\u2013e23.","DOI":"10.3399\/bjgp15X683113"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Cowan C, Healicon R, Robson I, Long WR, Barrett J, Fay M, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. <i>Heart<\/i> 2013; 99: 1166\u20131172.","DOI":"10.1136\/heartjnl-2012-303472"},{"key":"16","unstructured":"16. National Clinical Guideline Centre (UK). Atrial Fibrillation: The management of atrial fibrillation. London: 2014. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25340-239 (accessed June 18, 2019)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. <i>Circulation<\/i> 2014; 129: 837\u2013847.","DOI":"10.1161\/CIRCULATIONAHA.113.005119"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: A prospective cohort of Shinken Database 2004. <i>Circ J<\/i> 2008; 72: 914\u2013920.","DOI":"10.1253\/circj.72.914"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. <i>J Am Coll Cardiol<\/i> 2008; 51: 818\u2013825.","DOI":"10.1016\/j.jacc.2007.11.035"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. <i>Circulation<\/i> 2012; 126: 1185\u20131193.","DOI":"10.1161\/CIRCULATIONAHA.112.114967"},{"key":"21","unstructured":"21. Authors\/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>Eur Heart J<\/i> 2014; 35: 2541\u20132619."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. <i>Stroke<\/i> 2008; 39: 1740\u20131745.","DOI":"10.1161\/STROKEAHA.107.504993"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ma C. Current antithrombotic treatment in East Asia: Some perspectives on anticoagulation and antiplatelet therapy. <i>Thromb Haemost<\/i> 2012; 107: 1014\u20131018.","DOI":"10.1160\/TH11-04-0214"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. <i>Stroke<\/i> 2013; 44: 1891\u20131896.","DOI":"10.1161\/STROKEAHA.113.000990"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. <i>Europace<\/i> 2015; 17(Suppl 2): ii31\u2013ii39.","DOI":"10.1093\/europace\/euv231"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kaab S. Genome-wide association studies of atrial fibrillation: Past, present, and future. <i>Cardiovasc Res<\/i> 2011; 89: 701\u2013709.","DOI":"10.1093\/cvr\/cvr001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Proietti M, Lip GY. Major outcomes in atrial fibrillation patients with one risk factor: Impact of time in therapeutic range. Observations from the SPORTIF Trials. <i>Am J Med<\/i> 2016; 129: 1110\u20131116.","DOI":"10.1016\/j.amjmed.2016.03.024"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. <i>J Am Coll Cardiol<\/i> 2017; 69: 2779\u20132790.","DOI":"10.1016\/j.jacc.2017.03.600"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. <i>Circ Cardiovasc Qual Outcomes<\/i> 2011; 4: 14\u201321.","DOI":"10.1161\/CIRCOUTCOMES.110.958108"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D, et al. Evaluation of patients\u2019 attitudes towards stroke prevention and bleeding risk in atrial fibrillation. <i>Thromb Haemost<\/i> 2014; 111: 465\u2013473.","DOI":"10.1160\/TH13-05-0424"},{"key":"31","unstructured":"31. Hellfritzsch M, Grove EL, Husted SE, Rasmussen L, Poulsen BK, Johnsen SP, et al. Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. <i>Europace<\/i> 2017; 19: 1091\u20131095."}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/12\/83_CJ-19-0546\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T11:48:06Z","timestamp":1575287286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/12\/83_CJ-19-0546\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0546","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]}}}